APOE interacts with age to modify rate of decline in cognitive and brain changes in Alzheimer's disease

Yu Ling Chang, Christine Fennema-Notestine, Dominic Holland, Linda K. McEvoy, Nikki Stricker, David P. Salmon, Anders M. Dale, Mark W. Bondi

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Objective To determine (1) whether age-standardized cognitive declines and brain morphometric change differ between Young-Old patients with Alzheimer's disease (YOAD) and Very-Old patients with Alzheimer's disease (VOAD), and (2) whether the apolipoprotein E (APOE) genotype modifies these neuropsychological and morphometric changes. Methods Baseline and 12-month follow-up neuropsychological and morphometric measures were examined for healthy control subjects and patients with AD. The two AD groups were divided further into subgroups on the basis of the presence of at least one APOE ε4 allele. Results The YOAD group showed more severe deficits and steeper declines in cognition than the VOAD group. Moreover, the presence of an APOE ε4 allele had a more deleterious effect on the YOAD group than the VOAD group on cognition and brain structure both cross-sectionally and longitudinally. Conclusions Results underscore the importance of integrating an individual's age and genetic susceptibility - and their interaction - when examining neuropsychological and neuroimaging changes in the early stages of Alzheimer's disease.

Original languageEnglish (US)
Pages (from-to)336-348
Number of pages13
JournalAlzheimer's and Dementia
Volume10
Issue number3
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Apolipoproteins E
Alzheimer Disease
Brain
Apolipoprotein E4
Cognition
Alleles
Genetic Predisposition to Disease
Cognitive Dysfunction
Neuroimaging
Healthy Volunteers
Genotype

Keywords

  • Alzheimer's disease
  • APOE genotype
  • Cognition
  • Longitudinal
  • Magnetic resonance imaging
  • Morphometry

ASJC Scopus subject areas

  • Epidemiology
  • Health Policy
  • Developmental Neuroscience
  • Clinical Neurology
  • Geriatrics and Gerontology
  • Cellular and Molecular Neuroscience
  • Psychiatry and Mental health

Cite this

Chang, Y. L., Fennema-Notestine, C., Holland, D., McEvoy, L. K., Stricker, N., Salmon, D. P., ... Bondi, M. W. (2014). APOE interacts with age to modify rate of decline in cognitive and brain changes in Alzheimer's disease. Alzheimer's and Dementia, 10(3), 336-348. https://doi.org/10.1016/j.jalz.2013.05.1763

APOE interacts with age to modify rate of decline in cognitive and brain changes in Alzheimer's disease. / Chang, Yu Ling; Fennema-Notestine, Christine; Holland, Dominic; McEvoy, Linda K.; Stricker, Nikki; Salmon, David P.; Dale, Anders M.; Bondi, Mark W.

In: Alzheimer's and Dementia, Vol. 10, No. 3, 01.01.2014, p. 336-348.

Research output: Contribution to journalArticle

Chang, YL, Fennema-Notestine, C, Holland, D, McEvoy, LK, Stricker, N, Salmon, DP, Dale, AM & Bondi, MW 2014, 'APOE interacts with age to modify rate of decline in cognitive and brain changes in Alzheimer's disease', Alzheimer's and Dementia, vol. 10, no. 3, pp. 336-348. https://doi.org/10.1016/j.jalz.2013.05.1763
Chang, Yu Ling ; Fennema-Notestine, Christine ; Holland, Dominic ; McEvoy, Linda K. ; Stricker, Nikki ; Salmon, David P. ; Dale, Anders M. ; Bondi, Mark W. / APOE interacts with age to modify rate of decline in cognitive and brain changes in Alzheimer's disease. In: Alzheimer's and Dementia. 2014 ; Vol. 10, No. 3. pp. 336-348.
@article{ff28c598207e4ce8ba4a45f8e8f8ce7f,
title = "APOE interacts with age to modify rate of decline in cognitive and brain changes in Alzheimer's disease",
abstract = "Objective To determine (1) whether age-standardized cognitive declines and brain morphometric change differ between Young-Old patients with Alzheimer's disease (YOAD) and Very-Old patients with Alzheimer's disease (VOAD), and (2) whether the apolipoprotein E (APOE) genotype modifies these neuropsychological and morphometric changes. Methods Baseline and 12-month follow-up neuropsychological and morphometric measures were examined for healthy control subjects and patients with AD. The two AD groups were divided further into subgroups on the basis of the presence of at least one APOE ε4 allele. Results The YOAD group showed more severe deficits and steeper declines in cognition than the VOAD group. Moreover, the presence of an APOE ε4 allele had a more deleterious effect on the YOAD group than the VOAD group on cognition and brain structure both cross-sectionally and longitudinally. Conclusions Results underscore the importance of integrating an individual's age and genetic susceptibility - and their interaction - when examining neuropsychological and neuroimaging changes in the early stages of Alzheimer's disease.",
keywords = "Alzheimer's disease, APOE genotype, Cognition, Longitudinal, Magnetic resonance imaging, Morphometry",
author = "Chang, {Yu Ling} and Christine Fennema-Notestine and Dominic Holland and McEvoy, {Linda K.} and Nikki Stricker and Salmon, {David P.} and Dale, {Anders M.} and Bondi, {Mark W.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.jalz.2013.05.1763",
language = "English (US)",
volume = "10",
pages = "336--348",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - APOE interacts with age to modify rate of decline in cognitive and brain changes in Alzheimer's disease

AU - Chang, Yu Ling

AU - Fennema-Notestine, Christine

AU - Holland, Dominic

AU - McEvoy, Linda K.

AU - Stricker, Nikki

AU - Salmon, David P.

AU - Dale, Anders M.

AU - Bondi, Mark W.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Objective To determine (1) whether age-standardized cognitive declines and brain morphometric change differ between Young-Old patients with Alzheimer's disease (YOAD) and Very-Old patients with Alzheimer's disease (VOAD), and (2) whether the apolipoprotein E (APOE) genotype modifies these neuropsychological and morphometric changes. Methods Baseline and 12-month follow-up neuropsychological and morphometric measures were examined for healthy control subjects and patients with AD. The two AD groups were divided further into subgroups on the basis of the presence of at least one APOE ε4 allele. Results The YOAD group showed more severe deficits and steeper declines in cognition than the VOAD group. Moreover, the presence of an APOE ε4 allele had a more deleterious effect on the YOAD group than the VOAD group on cognition and brain structure both cross-sectionally and longitudinally. Conclusions Results underscore the importance of integrating an individual's age and genetic susceptibility - and their interaction - when examining neuropsychological and neuroimaging changes in the early stages of Alzheimer's disease.

AB - Objective To determine (1) whether age-standardized cognitive declines and brain morphometric change differ between Young-Old patients with Alzheimer's disease (YOAD) and Very-Old patients with Alzheimer's disease (VOAD), and (2) whether the apolipoprotein E (APOE) genotype modifies these neuropsychological and morphometric changes. Methods Baseline and 12-month follow-up neuropsychological and morphometric measures were examined for healthy control subjects and patients with AD. The two AD groups were divided further into subgroups on the basis of the presence of at least one APOE ε4 allele. Results The YOAD group showed more severe deficits and steeper declines in cognition than the VOAD group. Moreover, the presence of an APOE ε4 allele had a more deleterious effect on the YOAD group than the VOAD group on cognition and brain structure both cross-sectionally and longitudinally. Conclusions Results underscore the importance of integrating an individual's age and genetic susceptibility - and their interaction - when examining neuropsychological and neuroimaging changes in the early stages of Alzheimer's disease.

KW - Alzheimer's disease

KW - APOE genotype

KW - Cognition

KW - Longitudinal

KW - Magnetic resonance imaging

KW - Morphometry

UR - http://www.scopus.com/inward/record.url?scp=84899631915&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899631915&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2013.05.1763

DO - 10.1016/j.jalz.2013.05.1763

M3 - Article

C2 - 23896613

AN - SCOPUS:84899631915

VL - 10

SP - 336

EP - 348

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 3

ER -